Resurgence in M&A Activity

mergers and acquisitions (M&A) ⁤are gaining momentum ⁢after a⁢ slowdown following the COVID-19 pandemic. Factors contributing to this rebound include a more favorable regulatory ⁣climate and easing economic pressures from high⁤ interest rates and inflation. According to Bank of​ America, U.S. M&A deals year-to-date through October are tracking only 5%⁤ below last⁢ year’s​ levels, signaling growing optimism within the financial⁢ services industry.

Raymond James Upgrade and Price Target

On ⁤Monday, November‌ 8, 2025, Raymond James⁣ upgraded Universal Health Services (UHS) from a “Market perform” rating to “Outperform.” ‍Analyst John ransom ⁣set a $270 ⁤target price for UHS shares, representing approximately a 19% increase over the company’s closing price on the preceding Friday. This upgrade ⁣reflects positive performance in UHS’s third ‍quarter, exceeding company guidance.

Ransom noted revisions to ⁢future ⁢earnings‍ estimates: ⁢a roughly 7% increase for 2026 EBITDA and a 6% increase‌ for⁢ 2027 EBITDA. These adjustments ⁤are⁤ attributed to ​both improved operational efficiency​ and higher DPPs (Daily Patient rates). Raymond James’s 2026 and 2027 EBITDA estimates now exceed consensus estimates by approximately ⁢1.6% and 1.8%, respectively.

Other Potential ⁤Targets

Bank of America’s list of potential M&A ​candidates also included:

• Match Group
• Bio-Techne
• Paycom Software

Universal ​Health Services: Company Overview

Universal Health ‍Services (UHS) is a provider of hospital and healthcare services, ​operating acute care hospitals, surgical centers, ​and behavioral health facilities.⁢ As of November 8, 2025, the company ​operates facilities across ⁣the ‌United States⁤ and Puerto Rico.UHS’s financial performance is closely tied ⁣to factors ⁤such as patient ‌volume,⁢ reimbursement rates,‌ and operational efficiency.